Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
50 participants
INTERVENTIONAL
2012-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who undergoing lung resection surgery usually receive one lung ventilation (OLV). Decrease of systemic oxygenation occurs during OLV due to intrapulmonary shunt. During OLV, significant decrease in cerebral oxygenation (SctO2) is also known to occur and low SctO2 is related to postoperative complications.
Because the endpoint of hemodynamic optimization is to improve oxygen delivery to major organs, understanding how the administration of vasoactive agents affects cerebral perfusion and oxygenation, the most important organ in the body is of major clinical relevance. Recently published studies show that near-infrared spectroscopy (NIRS)-guided brain protection protocols might lead to reduced neurocognitive complications and improved postoperative outcomes.
However, there have been no data on which agent between dopamine and phenylephrine, the most commonly used aged during operation against hypotension, is better in maintaining cerebral oxygen saturation during thoracic surgery. Therefore, the investigators try to compare dopamine and phenylephrine continuous infusion in respect to maintaining SctO2 in major thoracic surgery.
In addition, acute kidney injury (AKI) develops in around 6% of patients after lung resection surgery and AKI is related to poor prognosis and prolonged duration of hospital admission.Therefore, the investigators also tried to find which agent is better to maintain urinary output during operation and reduce postoperative AKI. The investigators also found there is difference in postoperative delirium incidence between dopamine and phenylephrine continuous infusion.
The primary aims of the study were (i) to investigate the effect of phenylephrine and dopamine continuous infusion on cerebral SctO2 (ii) to identify the hemodynamic variables \[mean blood pressure, cardiac output, heart rate (HR), stroke volume (SV)\] which are responsible for the changes in cerebral SctO2 induced by phenylephrine and dopamine treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dopamine
dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
dopamine
continuous infusion during operation
phenylephrine
Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
phenylephrine
continuous infusion of phenylephrine during operation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dopamine
continuous infusion during operation
phenylephrine
continuous infusion of phenylephrine during operation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American society of anesthesia physical status I-III
Exclusion Criteria
* Poorly controlled hypertension (systolic arterial pressure ≥160 mm Hg)
* Cerebrovascular disease
* Poorly controlled diabetes mellitus (blood glucose ≥200 mg/dl)
* Diuretics or antidepressant use before operation
* Renal insufficiency (creatinine\>1.5 mg/dl)
* Cerebral infarction
* Documented coagulopathy
65 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyun Joo Ahn
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyun Joo Ahn
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung medical center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hyun Joo Ahn
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-09-058
Identifier Type: -
Identifier Source: org_study_id